# EDGAR Filing Document

**Accession Number:** 0001690585
**File Stem:** 0001992260-25-000008
**Filing Date:** 2025-11
**Character Count:** 9529
**Document Hash:** 60512825317adfdd7a29ea62588f26f7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001992260-25-000008.hdr.sgml**: 20251114

**ACCESSION NUMBER**: 0001992260-25-000008

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251113

**FILED AS OF DATE**: 20251114

**DATE AS OF CHANGE**: 20251114

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Randhawa Simrat
- **CENTRAL INDEX KEY:** 0001992260

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38541
- **FILM NUMBER:** 251489102

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dianthus Therapeutics, Inc. /DE/
- **CENTRAL INDEX KEY:** 0001690585
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 929-999-4055

**MAIL ADDRESS:**
- **STREET 1:** 7 TIMES SQUARE
- **STREET 2:** 43RD FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Magenta Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20161121

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Randhawa Simrat<br><sub>(Last) (First) (Middle)</sub><br>C/O DIANTHUS THERAPEUTICS, INC.<br>7 TIMES SQUARE, 43RD FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10036<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-13 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_EVP, Head of R&D_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Dianthus Therapeutics, Inc. /DE/ [ DNTH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-13 |  | M<sup>(1)</sup> |  | 83978 | A | $8.44 | 87978 | D |  |
| Common Stock | 2025-11-13 |  | M<sup>(1)</sup> |  | 3529 | A | $17.88 | 91507 | D |  |
| Common Stock | 2025-11-13 |  | S<sup>(1)</sup> |  | 26166 | D | 35.80<sup>(2)</sup> | 65341 | D |  |
| Common Stock | 2025-11-13 |  | S<sup>(1)</sup> |  | 42765 | D | 37.04<sup>(3)</sup> | 22576 | D |  |
| Common Stock | 2025-11-13 |  | S<sup>(1)</sup> |  | 18576 | D | 37.72<sup>(4)</sup> | 4000 | D |  |
| Common Stock | 2025-11-14 |  | M<sup>(1)</sup> |  | 40287 | A | $17.88 | 44287 | D |  |
| Common Stock | 2025-11-14 |  | M<sup>(1)</sup> |  | 37494 | A | $21.77 | 81781 | D |  |
| Common Stock | 2025-11-14 |  | M<sup>(1)</sup> |  | 31250 | A | $22.07 | 113031 | D |  |
| Common Stock | 2025-11-14 |  | S<sup>(1)</sup> |  | 109031 | D | $38.14 | 4000 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $8.44 | 2025-11-13 |  | M<sup>(1)</sup> |  |  | 83978 | <sup>(5)</sup> | 2032-06-06 | Common Stock | 83978 | $0 | 11996 | D |  |
| Stock Option (Right to Buy) | $17.88 | 2025-11-13 |  | M<sup>(1)</sup> |  |  | 3529 | <sup>(6)</sup> | 2034-01-23 | Common Stock | 3529 | $0 | 116471 | D |  |
| Stock Option (Right to Buy) | $17.88 | 2025-11-14 |  | M<sup>(1)</sup> |  |  | 40287 | <sup>(6)</sup> | 2034-01-23 | Common Stock | 40287 | $0 | 76184 | D |  |
| Stock Option (Right to Buy) | $21.77 | 2025-11-14 |  | M<sup>(1)</sup> |  |  | 37494 | <sup>(7)</sup> | 2034-05-22 | Common Stock | 37494 | $0 | 62506 | D |  |
| Stock Option (Right to Buy) | $22.07 | 2025-11-14 |  | M<sup>(1)</sup> |  |  | 31250 | <sup>(8)</sup> | 2035-02-03 | Common Stock | 31250 | $0 | 118750 | D |  |

---

### Footnotes:

(1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.

(2) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.48 to $36.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

(3) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.48 to $37.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

(4) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.48 to $38.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

(5) The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

(6) The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

(7) The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

(8) The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

**Signature:** /s/ Adam Veness, as attorney-in-fact for Simrat Randhawa  
**Date:** 2025-11-14

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**